Off-the-Shelf CAR-Ts take on lupus and more
NCT ID NCT07596680
First seen May 21, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This early-phase study tests a universal (off-the-shelf) CAR-T cell therapy called RD06-05 in 30 people with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. The goal is to see if it is safe and can reduce disease activity by targeting faulty immune cells. Participants receive a single dose and are monitored for side effects and improvements in their condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 220127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.